{
    "clinical_study": {
        "@rank": "50339", 
        "arm_group": [
            {
                "arm_group_label": "Daivonex", 
                "arm_group_type": "Active Comparator", 
                "description": "topical application"
            }, 
            {
                "arm_group_label": "vehicle", 
                "arm_group_type": "Placebo Comparator", 
                "description": "topical application"
            }, 
            {
                "arm_group_label": "M518101", 
                "arm_group_type": "Experimental", 
                "description": "topical application"
            }
        ], 
        "brief_summary": {
            "textblock": "M5181 - a novel vitamin D3 analogue - is currently under development for the treatment of\n      plaque psoriasis and is being developed as a topical ointment formulation (M518101)\n\n      Clinical and non-clinical studies indicate that M5181 is an effective treatment for plaque\n      psoriasis.\n\n      Based on the results of previous phase II trials the phase III trial has been designed to\n      evaluate efficacy and safety of an 8-week treatment period with 50 \u03bcg/g M518101 in a larger\n      population of patients with stable plaque psoriasis."
        }, 
        "brief_title": "Efficacy Study Comparing Topical M518101 and Vitamin D3 in Adult Psoriasis Patients", 
        "completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Plaque Psoriasis", 
        "condition_browse": {
            "mesh_term": "Psoriasis"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female patients aged 18 years or older on the day of signing the informed\n             consent form (ICF)\n\n          -  Psoriasis patients with up to 20% affected body surface area ( BSA) (not including\n             face or scalp)\n\n          -  Investigator Global Assessment(IGA) of moderate to severe and who are suitable for\n             topical therapy\n\n        Exclusion Criteria:\n\n          -  Pregnant or lactating females;\n\n          -  Patients with known allergic reactions, irritations or sensitivity to vitamin D3\n             derivatives drug hypersensitivity to other components of the investigational\n             products;\n\n          -  Patients who have been treated with topical steroids, topical immunosuppressive/\n             immunomodulative drugs, topical vitamin D3 derivative, topical retinoids, anthralin,\n             coal tar (except when used as shampoo) salicylic acid within 14 days of randomization\n\n          -  Patients, who in the opinion of the investigator, have clinically relevant history or\n             presence of any disease, any other skin disorder, any chronic medical condition which\n             is not well controlled or surgical history which may interfere with the conduct of\n             the trial\n\n          -  Patients whose calcium test at screening exceed the upper limit of reference range\n             (including serum calcium, albumin, phosphate, parathyroid hormone);\n\n          -  Patients who have used any study drug (including experimental biologics) and/or\n             participated in any clinical trial within the last 60 days before the day of\n             randomization\n\n          -  Patients who have been treated with any biologics for their psoriasis within 30 days\n             or 5 half-lives (whichever is longer) of the biologic before the day of randomization\n             the longest documented half-life of the biologic should be used to calculate the 5\n             half-lives;\n\n          -  Patients who have been treated with phototherapy (laser, oral steroids, oral\n             retinoid, oral immunosuppressive/immunomodulative drugs, cytostatics, cyclosporine or\n             methotrexate within 30 days of randomization"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "725", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 28, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01989429", 
            "org_study_id": "M518101-EU04", 
            "secondary_id": "2013\u2010001632\u201021"
        }, 
        "intervention": {
            "arm_group_label": [
                "Daivonex", 
                "vehicle", 
                "M518101"
            ], 
            "description": "8-week comparative treatment period ( twice daily application) followed by a maximum 8-week period to evaluate time to relapse", 
            "intervention_name": "M518101", 
            "intervention_type": "Drug", 
            "other_name": [
                "vitamin D3", 
                "psoriasis treatment"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Cholecalciferol", 
                "Vitamin D", 
                "Ergocalciferols", 
                "Vitamins"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "psoriasis", 
            "Vitamin D3", 
            "topical", 
            "ointments"
        ], 
        "lastchanged_date": "March 7, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Graz", 
                        "country": "Austria", 
                        "zip": "8036"
                    }, 
                    "name": "Universit\u00e4tsklinik f\u00fcr Dermatologie und Venerologie,"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Georgiev Ilko Bakardzhiev, Assoc Prof Dr", 
                    "phone": "00359 52 786 913"
                }, 
                "facility": {
                    "address": {
                        "city": "Varna", 
                        "country": "Bulgaria", 
                        "zip": "9002"
                    }, 
                    "name": "DCC \"Chaika\" EOOD"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Diamant Thaci, Prof.Dr.med"
                }, 
                "facility": {
                    "address": {
                        "city": "Lubeck", 
                        "country": "Germany", 
                        "zip": "23538"
                    }, 
                    "name": "Universitatsklinikum Schleswig-Holstein"
                }, 
                "investigator": {
                    "last_name": "Daimant Thaci, Prof.Dr.med", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Miskolc", 
                        "country": "Hungary", 
                        "state": "Csabai Kapu 9-11,", 
                        "zip": "H-3529"
                    }, 
                    "name": "Semmelweis Hospital"
                }, 
                "investigator": {
                    "last_name": "Zsuzsanna K\u00e1rolyi, Dr", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kaunas", 
                        "country": "Lithuania"
                    }, 
                    "name": "PI Hospital of Lithuanian University of Health Sciences"
                }, 
                "investigator": {
                    "last_name": "Skaidra Valiukeviciene, Dr Prof", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Warsaw", 
                        "country": "Poland"
                    }, 
                    "name": "CSK MON Wojskowego Instytutu Medycznego"
                }, 
                "investigator": {
                    "last_name": "Witold Owczarek, Prof", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Austria", 
                "Bulgaria", 
                "Germany", 
                "Hungary", 
                "Lithuania", 
                "Poland"
            ]
        }, 
        "number_of_arms": "3", 
        "official_title": "A Randomized, Double-blind, Parallel Group Phase III Multi-center Trial to Compare Twice Daily Topical Application of M518101, Daivonex\u00ae and Vehicle in Patients With Plaque Psoriasis III", 
        "overall_contact": {
            "email": "elisabeth.rowold@bioskin.de", 
            "last_name": "Elisabeth Rowold, Ph.D.", 
            "phone": "+49 40 60 68 97 39"
        }, 
        "overall_contact_backup": {
            "email": "henning.werner@bioskin.de", 
            "last_name": "Henning Werner", 
            "phone": "+49 40 60 68 97 50"
        }, 
        "overall_official": {
            "affiliation": "University of Lubeck, Dermatology Department", 
            "last_name": "D Thaci, Prof.Dr", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Germany: Federal Institute for Drugs and Medical Devices", 
                "Lithuania: State Medicine Control Agency - Ministry of Health", 
                "Hungary: National Institute of Pharmacy", 
                "Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products", 
                "Ukraine: Ministry of Health", 
                "Bulgaria: Ministry of Health", 
                "Romania: National Medicines Agency", 
                "Austria: Austrian Medicines and Medical Devices Agency"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "% reduction in mPASI(modified psoriasis area and severity index)  will be measured", 
            "measure": "Severity of psoriasis", 
            "safety_issue": "No", 
            "time_frame": "8 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01989429"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "if mPASI is reduced  by 50% or more at V7 , patients will be followed  up for a further 8 weeks to evaluate time to relapse", 
            "measure": "Duration of response following 8 week treatment", 
            "safety_issue": "No", 
            "time_frame": "8 weeks"
        }, 
        "source": "Maruho Europe Limited", 
        "sponsors": {
            "collaborator": {
                "agency": "Maruho Co., Ltd.", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Maruho Europe Limited", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}